Polymer-sirolimus-eluting stents in de novo lesions.
Sirolimus has been shown to inhibit vascular smooth muscle cell proliferation and migration. Stents coated with a mixture of polymer and active drug achieved near total inhibition of neointimal hyperplasia in patients with de novo coronary lesions. Larger, randomized trials confirmed these initial results to a large extent; late luminal loss was not only reduced by > 70% in patients with type A lesions, but also in complex situations such as diabetic patients, long lesions, and small vessels < 2.5 mm. Registries containing several thousand patients, however, indicate that under realistic conditions the flawless results of the initial studies could not be reproduced in all patient groups.
Schuler
Gerhard
G
Herzzentrum GmbH, University of Leipzig, Germany. schug@medizin.uni-leipzig.de
D000287:Administration, Topical; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000097:blood / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000097:blood / Q000628:therapy*; D003331:Coronary Vessels / Q000187:drug effects; D006801:Humans; D011108:Polymers; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D015607:Stents
D000903:Antibiotics, Antineoplastic; D020099:Coated Materials, Biocompatible; D011108:Polymers; D020123:Sirolimus